Related Experiment Video
Updated: Aug 14, 2025
A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood
Published on: February 8, 2016
Validation of a flow-cytometry-based red blood cell antigen phenotyping method
Robert Liwski1,2, Gwen Clarke3,4, Calvino Cheng1,2
1Department of Pathology and Laboratory Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Insights
Flow cytometry offers a high-throughput, low-cost method for red blood cell (RBC) phenotyping, using minimal reagents and achieving 100% concordance with traditional methods. This validated technique enables automated interpretation and could revolutionize blood transfusion services.
Area of Science:
- Hematology
- Immunology
- Biotechnology
Background:
- Current red blood cell (RBC) phenotyping relies on visual detection of antigen-antibody interactions.
- Existing methods require large volumes of reagents and patient cells, limiting throughput and increasing costs.
- Limitations include the need for significant reagent and cell volumes for visually detectable reactions.
Purpose of the Study:
- To develop and validate flow cytometry for high-throughput RBC phenotyping.
- To enable fluorescence-based detection of antibody binding using minimal reagent volumes.
- To establish an automated, quantitative method for RBC phenotyping.
Main Methods:
- RBC phenotyping was performed using flow cytometry with commercially available monoclonal direct and indirect typing antisera.
- Seventy samples were analyzed using both flow cytometry and standard manual tube agglutination assays.
- Antisera included anti-C, -E, -c, -e, -K, -Jk a, -Jk b, -k, -Fy a, -Fy b, -S, and -s.
Main Results:
- Flow cytometry-based phenotyping achieved 100% concordance with manual tube agglutination assays across all tested antigens.
- The flow cytometry method required significantly lower reagent volumes (0.5-1 μl per antigen) compared to manual methods (50 μl per antigen).
- High throughput and automation potential were demonstrated.
Conclusions:
- Flow cytometry is a validated and effective method for RBC phenotyping.
- This technique offers advantages such as automation, quantitative results, and minimal reagent use.
- The method is suitable for high-throughput, low-cost phenotyping in blood suppliers and hospital blood transfusion services.
Background And Objectives:
Current manual and automated phenotyping methods are based on visual detection of the antigen-antibody interaction. This approach has several limitations including the use of large volumes of patient and reagent red blood cells (RBCs) and antisera to produce a visually detectable reaction. We sought to determine whether the flow cytometry could be developed and validated to perform RBC phenotyping to enable a high-throughput method of phenotyping using comparatively miniscule reagent volumes via fluorescence-based detection of antibody binding.
Materials And Methods:
RBC phenotyping by flow cytometry was performed using monoclonal direct typing antisera (human IgM): anti-C, -E, -c, -e, -K, -Jka , -Jkb and indirect typing antisera (human IgG): anti-k, -Fya , -Fyb , -S, -s that are commercially available and currently utilized in our blood transfusion services (BTS) for agglutination-based phenotyping assays.
Results:
Seventy samples were tested using both flow-cytometry-based-phenotyping and a manual tube standard agglutination assay. For all the antigens tested, 100% concordance was achieved. The flow-cytometry-based method used minimal reagent volume (0.5-1 μl per antigen) compared with the volumes required for manual tube standard agglutination (50 μl per antigen) CONCLUSION: This study demonstrates the successful validation of flow-cytometry-based RBC phenotyping. Flow cytometry offers many benefits compared to common conventional RBC phenotyping methods including high degrees of automation, quantitative assessment with automated interpretation of results and extremely low volumes of reagents. This method could be used for high-throughput, low-cost phenotyping for both blood suppliers and hospital BTS.
